Awaiting development: Guidance and quality standards
Showing 251 to 260 of 391
| Title | Type |
|---|---|
| Point-of-care lipid tests for cardiovascular disease prevention in primary and community care | HealthTech guidance |
| Port Delivery Platform with ranibizumab for treating wet age-related macular degeneration [ID3983] | Technology appraisal guidance |
| Povorcitinib for treating non-segmental vitiligo [GID-TA12019] | Technology appraisal guidance |
| Povorcitinib for treating prurigo nodularis [GID-TA12018] | Technology appraisal guidance |
| Pozelimab with cemdisiran for treating symptomatic generalised myasthenia gravis [ID6720] | Technology appraisal guidance |
| Prevention of dementia | Quality standard |
| Pridopidine for treating Huntington's disease [ID6525] | Technology appraisal guidance |
| Primary hyperparathyroidism | Quality standard |
| Pritelivir (AIC-316) for Herpes simplex virus 2 infection (HSV-2) [12367] | Technology appraisal guidance |
| Procalcitonin to guide decisions on stopping antibiotics in people with confirmed or highly suspected sepsis | HealthTech guidance |